Pfizer And Myovant Get FDA Nod For Myfembree

Pfizer Inc. and Myovant Sciences announced that the U.S. Food and Drug Administration has approved Myfembree, the first once-daily treatment for heavy menstrual bleeding associated with uterine fibroids. Under the collaboration terms, Myovant and Pfizer will jointly commercialize Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) in the U.S.

from RTT - Top Story https://ift.tt/3fsC4n4
via IFTTT